{rfName}
Ac

Indexed in

License and use

Citations

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Buges, CAuthor

Share

February 6, 2017
Publications
>
Meeting Abstract
No

Activity of aflibercept (Afli) in combination with FOLFIRI (F) for patients with metastatic colorectal cancer (mCRC) in a real-life setting in Spain: Final results of the retrospective study Named Patient Program.

Publicated to:Journal Of Clinical Oncology. 34 (4): 689-689 - 2016-02-01 34(4), DOI: 10.1200/jco.2016.34.4_suppl.689

Authors: Sastre, J; Feliu, J; Martinez, P; Buges, C; Mendez, JC; Alcaide, J; Garcia, T; Valladares, M; Marrupe, D; Delgado, I; Fernandez, MS; Valades, JIM; Juarez, A; Martinez, JMM; Lopez, A; Aldana, GAQ; Donnay, O; Vera, R; del Pozo, N; Frutos, IDD

Affiliations

Complejo Hosp Navarra, Med Oncol, Pamplona, Spain - Author
Complejo Hosp Univ Ourense, Orense, Spain - Author
Complexo Hosp Univ A Coruna, Serv Oncol, La Coruna, Spain - Author
Consorcio Hosp Gen Univ Valencia, Valencia, Spain - Author
Ctr Oncol Galicia, La Coruna, Spain - Author
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Dept Med Oncol, Barcelona, Spain - Author
Hosp Basurto, Bilbao, Spain - Author
Hosp Clin San Carlos, Madrid, Spain - Author
Hosp Costa del Sol, Dept Oncol, Marbella, Spain - Author
Hosp Galdacao Usansolo, Vizcaya, Spain - Author
Hosp Gen Elda, Elda, Spain - Author
Hosp Infanta Cristina, Badajoz, Spain - Author
Hosp Mostoles, Mostoles, Spain - Author
Hosp Univ Getafe, Getafe, Spain - Author
Hosp Univ La Princesa, Madrid, Spain - Author
Hosp Xeral Calde, Lugo, Spain - Author
Infanta Leonor Hosp, Madrid, Spain - Author
Translat Oncol Unit, Madrid, Spain - Author
Univ Autonoma Madrid, Fdn Jimenez Diaz, Madrid, Spain - Author
Univ Hosp Morales Meseguer, Hematol & Med Oncol Dept, Murcia, Spain - Author
See more

Abstract

Keywords

Good health and well-being

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Clinical Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2016, it was in position 5/217, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-06:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 2 (PlumX).
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 3 - Good Health and Well-Being, with a probability of 60% according to the mBERT algorithm developed by Aurora University.